$XLO
Xilio Therapeutics Inc

2023 Q2 Form 10-Q Financial Statement

#000155837023008676 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.898M $7.395M
YoY Change -16.95% 17.31%
% of Gross Profit
Research & Development $13.22M $16.13M
YoY Change -18.64% 8.12%
% of Gross Profit
Depreciation & Amortization $492.0K $499.0K
YoY Change 10.56% 13.41%
% of Gross Profit
Operating Expenses $20.12M $23.53M
YoY Change -18.07% 10.85%
Operating Profit -$20.12M -$23.53M
YoY Change -18.07% 10.85%
Interest Expense -$100.0K -$200.0K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $761.0K $880.0K
YoY Change -1347.54% -782.17%
Pretax Income -$19.36M -$22.65M
YoY Change -21.36% 6.06%
Income Tax
% Of Pretax Income
Net Earnings -$19.36M -$22.65M
YoY Change -21.36% 6.06%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70 -$0.83
Diluted Earnings Per Share -$0.70 -$0.83
COMMON SHARES
Basic Shares Outstanding 27.47M 27.47M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.38M $93.27M
YoY Change -52.71% -47.29%
Cash & Equivalents $75.40M $93.30M
Short-Term Investments
Other Short-Term Assets $3.042M $3.705M
YoY Change -15.43% -10.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.43M $96.98M
YoY Change -51.89% -46.45%
LONG-TERM ASSETS
Property, Plant & Equipment $6.798M $7.252M
YoY Change -8.65% -2.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $197.0K $232.0K
YoY Change -41.19% -35.38%
Total Long-Term Assets $13.93M $14.53M
YoY Change -7.84% -4.82%
TOTAL ASSETS
Total Short-Term Assets $78.43M $96.98M
Total Long-Term Assets $13.93M $14.53M
Total Assets $92.36M $111.5M
YoY Change -48.15% -43.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $945.0K $2.013M
YoY Change -32.98% -13.38%
Accrued Expenses $7.140M $6.483M
YoY Change -40.93% -11.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.145M $6.667M
YoY Change 114.37% 299.94%
Total Short-Term Liabilities $16.29M $16.19M
YoY Change -8.31% 32.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.548M
YoY Change -100.0% -80.68%
Other Long-Term Liabilities $7.000K $26.00K
YoY Change -91.46% -74.0%
Total Long-Term Liabilities $7.000K $26.00K
YoY Change -91.46% -74.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.29M $16.19M
Total Long-Term Liabilities $7.000K $26.00K
Total Liabilities $24.98M $26.71M
YoY Change -26.33% -11.64%
SHAREHOLDERS EQUITY
Retained Earnings -$291.1M -$271.8M
YoY Change 40.73% 49.12%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.38M $84.79M
YoY Change
Total Liabilities & Shareholders Equity $92.36M $111.5M
YoY Change -48.15% -43.21%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$19.36M -$22.65M
YoY Change -21.36% 6.06%
Depreciation, Depletion And Amortization $492.0K $499.0K
YoY Change 10.56% 13.41%
Cash From Operating Activities -$16.57M -$25.25M
YoY Change -1.09% 21.19%
INVESTING ACTIVITIES
Capital Expenditures $316.0K $170.0K
YoY Change -140.99% -33.07%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$316.0K -$170.0K
YoY Change -59.01% -33.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -992.0K -1.688M
YoY Change 4623.81% 33660.0%
NET CHANGE
Cash From Operating Activities -16.57M -25.25M
Cash From Investing Activities -316.0K -170.0K
Cash From Financing Activities -992.0K -1.688M
Net Change In Cash -17.88M -27.11M
YoY Change 1.9% 28.51%
FREE CASH FLOW
Cash From Operating Activities -$16.57M -$25.25M
Capital Expenditures $316.0K $170.0K
Free Cash Flow -$16.89M -$25.42M
YoY Change 5.66% 20.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001840233
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3165000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8945000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9189000
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40925
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Xilio Therapeutics, Inc.
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1623397
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
828 Winter Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2023Q1 dei City Area Code
CityAreaCode
857
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
524-2466
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
XLO
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27470702
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93271000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120385000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3705000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4111000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
96976000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124496000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1568000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1562000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7252000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7255000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5477000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5585000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
232000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
267000
CY2023Q1 us-gaap Assets
Assets
111505000
CY2022Q4 us-gaap Assets
Assets
139165000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2013000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3125000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6483000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
949000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
918000
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
6667000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
6667000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16194000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21119000
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
1548000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
26000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45000
CY2023Q1 us-gaap Liabilities
Liabilities
26713000
CY2022Q4 us-gaap Liabilities
Liabilities
33518000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27470534
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27439820
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27471607
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27425447
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
356543000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
354752000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271754000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-249108000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
84792000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105647000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111505000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139165000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16131000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14920000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7395000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6304000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
23526000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
21224000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23526000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21224000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
880000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-129000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
880000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-129000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22646000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22646000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21353000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21353000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27433252
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27433252
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27367377
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27367377
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105647000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1791000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22646000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
84792000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21353000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166121000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-22646000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21353000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
499000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
440000
CY2023Q1 xlo Noncash Interest Expense
NoncashInterestExpense
31000
CY2022Q1 xlo Noncash Interest Expense
NoncashInterestExpense
53000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1791000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2029000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-406000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-336000
CY2023Q1 xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-108000
CY2022Q1 xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-92000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1358000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-820000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3868000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1427000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-213000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-185000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25250000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20835000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
254000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-254000
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1667000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
21000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
21000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1688000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27108000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21094000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121947000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199606000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94839000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178512000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
209000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
119000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
310000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93271000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176959000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1568000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1553000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94839000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178512000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93300000
CY2023Q1 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Concentrations of Credit Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company holds all cash and cash equivalents at accredited financial institutions. Bank accounts in the United States are generally insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. Substantially all of the Company’s cash and cash equivalents are FDIC insured, including funds held through an insured cash sweep program. The Company has not experienced any losses in its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p>
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.82
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y5M4D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
47000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12134000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11673000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4882000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4418000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7252000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7255000
CY2023Q1 us-gaap Depreciation
Depreciation
500000
CY2022Q1 us-gaap Depreciation
Depreciation
400000
CY2023Q1 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
3640000
CY2022Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
3178000
CY2023Q1 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
1745000
CY2022Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
5413000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
829000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1536000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
269000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
200000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6483000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.95
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.83
CY2019Q3 xlo Lessee Operating Lease Area Leased
LesseeOperatingLeaseAreaLeased
27830
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2019Q3 xlo Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
P5Y
CY2023Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2022Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2022Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10302841
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8653472
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1791000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2029000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4960553
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.04
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
89000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1530505
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.69
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
156
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.69
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
403302
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.36
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6087600
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.74
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
962000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2060294
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6189829
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5046141

Files In Submission

Name View Source Status
0001558370-23-008676-index-headers.html Edgar Link pending
0001558370-23-008676-index.html Edgar Link pending
0001558370-23-008676.txt Edgar Link pending
0001558370-23-008676-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xlo-20230331.xsd Edgar Link pending
xlo-20230331x10q.htm Edgar Link pending
xlo-20230331xex10d2.htm Edgar Link pending
xlo-20230331xex31d1.htm Edgar Link pending
xlo-20230331xex31d2.htm Edgar Link pending
xlo-20230331xex32d1.htm Edgar Link pending
xlo-20230331_lab.xml Edgar Link unprocessable
xlo-20230331_def.xml Edgar Link unprocessable
xlo-20230331_cal.xml Edgar Link unprocessable
xlo-20230331_pre.xml Edgar Link unprocessable
xlo-20230331x10q_htm.xml Edgar Link completed